Literature DB >> 15745724

Fluoroquinolone prescribing in the United States: 1995 to 2002.

Jeffrey A Linder1, Elbert S Huang, Michael A Steinman, Ralph Gonzales, Randall S Stafford.   

Abstract

PURPOSE: To measure changes in the rate and type of fluoroquinolones prescribed in the United States from 1995 to 2002.
METHODS: We performed a longitudinal analysis of the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey of adult visits to physicians in ambulatory clinics and emergency departments throughout the United States from 1995 to 2002. The main outcomes were fluoroquinolone prescribing rates and prescribing in accordance with Food and Drug Administration approval as of December 2002.
RESULTS: Between 1995 and 2002, fluoroquinolones became the most commonly prescribed class of antibiotics to adults in the United States. Fluoroquinolone prescribing rose threefold, from 7 million visits in 1995 to 22 million visits in 2002 (P < 0.0001). Fluoroquinolone prescribing increased as a proportion of overall antibiotic prescribing (from 10% to 24%; P < 0.0001) and as a proportion of the U.S. population (from 39 to 106 prescriptions per 1000 adults; P < 0.001). These increases were due to the use of newer fluoroquinolones with activity against Streptococcus pneumoniae. Forty-two percent of fluoroquinolone prescriptions were for nonapproved diagnoses. Among patients receiving antibiotics, nonapproved fluoroquinolone prescribing increased over time (odds ratio = 1.18 per year; 95% confidence interval: 1.13 to 1.24).
CONCLUSION: Fluoroquinolone prescribing increased threefold in outpatient clinics and emergency departments in the United States from 1995 to 2002. Fluoroquinolones became the most commonly prescribed class of antibiotics to adults in 2002. Nonapproved fluoroquinolone prescribing was common and increased over time. Such prescribing patterns are likely to be followed by an increasing prevalence of fluoroquinolone-resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15745724     DOI: 10.1016/j.amjmed.2004.09.015

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  95 in total

1.  Assessing sensitivity to antibacterial topoisomerase II inhibitors.

Authors:  Sonia K Morgan-Linnell; Hiroshi Hiasa; Lynn Zechiedrich; John L Nitiss
Journal:  Curr Protoc Pharmacol       Date:  2007-12

2.  Regional variations in quinolone use in France and associated factors.

Authors:  A Gallini; F Taboulet; R Bourrel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-29       Impact factor: 3.267

3.  Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.

Authors:  P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal:  J Hosp Infect       Date:  2010-12       Impact factor: 3.926

4.  Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Andrew E Simor; Alex Kopp; Paula A Rochon; David N Juurlink
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

5.  Upgrading antibiotic use within a class: tradeoff between resistance and treatment success.

Authors:  Y Claire Wang; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-13       Impact factor: 11.205

6.  New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.

Authors:  Jean-Winoc Decousser; Imen Methlouthi; Patrick Pina; Anne Collignon; Pierre Allouch
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission.

Authors:  Victoire de Lastours; Françoise Chau; Florence Tubach; Blandine Pasquet; Etienne Ruppé; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

8.  Antibiotic prescribing over the last 16 years: fewer antibiotics but the spectrum is broadening.

Authors:  C Llor; J M Cots; M J Gaspar; M Alay; N Rams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-02-20       Impact factor: 3.267

9.  The association between fluoroquinolones and aortic dissection and aortic aneurysms: a systematic review and meta-analysis.

Authors:  Ian Wee; Brian Chin; Nicholas Syn; Keng Siang Lee; Jun Jie Ng; Andrew M T L Choong
Journal:  Sci Rep       Date:  2021-05-26       Impact factor: 4.379

10.  Excessive antibiotic use in men with prostatitis.

Authors:  Brent C Taylor; Siamak Noorbaloochi; Mary McNaughton-Collins; Christopher S Saigal; Min-Woong Sohn; Michel A Pontari; Mark S Litwin; Timothy J Wilt
Journal:  Am J Med       Date:  2008-05       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.